Overview

A Safety, Efficacy and Biomarker Study of JNJ-42847922 in Participants With Major Depressive Disorder

Status:
Completed
Trial end date:
2016-01-04
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of JNJ-42847922 in participants with Major Depressive Disorder (MDD).
Phase:
Phase 1
Details
Lead Sponsor:
Janssen-Cilag International NV
Treatments:
Diphenhydramine
Promethazine